company background image
2256

Abbisko Cayman SEHK:2256 Stock Report

Last Price

HK$3.90

Market Cap

HK$2.7b

7D

-5.1%

1Y

n/a

Updated

10 Aug, 2022

Data

Company Financials +
2256 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

2256 Stock Overview

Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, discovers and develops small molecule oncology therapies in Mainland China.

Abbisko Cayman Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Abbisko Cayman
Historical stock prices
Current Share PriceHK$3.90
52 Week HighHK$12.54
52 Week LowHK$3.11
Beta0
1 Month Change-2.50%
3 Month Change0%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-68.55%

Recent News & Updates

Jun 08
We Think Abbisko Cayman (HKG:2256) Can Afford To Drive Business Growth

We Think Abbisko Cayman (HKG:2256) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Shareholder Returns

2256HK BiotechsHK Market
7D-5.1%0.8%-0.6%
1Yn/a-54.2%-23.8%

Return vs Industry: Insufficient data to determine how 2256 performed against the Hong Kong Biotechs industry.

Return vs Market: Insufficient data to determine how 2256 performed against the Hong Kong Market.

Price Volatility

Is 2256's price volatile compared to industry and market?
2256 volatility
2256 Average Weekly Movement6.1%
Biotechs Industry Average Movement7.9%
Market Average Movement6.5%
10% most volatile stocks in HK Market12.8%
10% least volatile stocks in HK Market3.1%

Stable Share Price: 2256 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 2256's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2016160Yao-Chang Xuhttps://www.abbisko.com

Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, discovers and develops small molecule oncology therapies in Mainland China. The company’s product candidates are primarily small molecules that focus on small molecule precision oncology and small molecule immuno-oncology therapeutic areas. It is also involved in the research and development in areas of biomedical and biotechnology; and provision of technical and technical consultation services.

Abbisko Cayman Limited Fundamentals Summary

How do Abbisko Cayman's earnings and revenue compare to its market cap?
2256 fundamental statistics
Market CapCN¥2.35b
Earnings (TTM)-CN¥1.81b
Revenue (TTM)CN¥22.68m

103.8x

P/S Ratio

-1.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
2256 income statement (TTM)
RevenueCN¥22.68m
Cost of RevenueCN¥0
Gross ProfitCN¥22.68m
Other ExpensesCN¥1.83b
Earnings-CN¥1.81b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-2.58
Gross Margin100.00%
Net Profit Margin-7,979.87%
Debt/Equity Ratio0%

How did 2256 perform over the long term?

See historical performance and comparison